Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

344 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≤50 copies/mL: does estimated glomerular filtration rate matter?
Vergori A, Gagliardini R, Gianotti N, Gori A, Lichtner M, Saracino A, De Vito A, Cascio A, Di Biagio A, Monforte AD, Antinori A, Cozzi-Lepri A; ICONA Foundation Study Network. Vergori A, et al. Among authors: de vito a. Int J Antimicrob Agents. 2020 Dec;56(6):106154. doi: 10.1016/j.ijantimicag.2020.106154. Epub 2020 Sep 10. Int J Antimicrob Agents. 2020. PMID: 32919008
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort.
Bandera A, Lorenzini P, Taramasso L, Cozzi-Lepri A, Lapadula G, Mussini C, Saracino A, Ceccherini-Silberstein F, Puoti M, Quiros-Roldan E, Montagnani F, Antinori A, d'Arminio Monforte A, Gori A; Icona Foundation Cohort. Bandera A, et al. J Viral Hepat. 2021 May;28(5):779-786. doi: 10.1111/jvh.13488. Epub 2021 Mar 11. J Viral Hepat. 2021. PMID: 33600068
Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study.
Taramasso L, De Vito A, Ricci ED, Orofino G, Squillace N, Menzaghi B, Molteni C, Gulminetti R, De Socio GV, Pellicanò GF, Sarchi E, Celesia BM, Calza L, Rusconi S, Valsecchi L, Martinelli CV, Cascio A, Maggi P, Vichi F, Angioni G, Guadagnino G, Cenderello G, Dentone C, Bandera A, Falasca K, Bonfanti P, Di Biagio A, Madeddu G; Behalf of the CISAI Study Group. Taramasso L, et al. Among authors: de socio gv, de vito a. AIDS Patient Care STDS. 2021 Sep;35(9):342-353. doi: 10.1089/apc.2021.0089. AIDS Patient Care STDS. 2021. PMID: 34524918
Predictors of Virological Failure Among People Living with HIV Switching from an Effective First-Line Antiretroviral Regimen.
Magnasco L, Pincino R, Pasculli G, Bouba Y, Saladini F, Bavaro DF, De Vito A, Lattanzio R, Corsini R, Zazzi M, Incardona F, Rossetti B, Bezenchek A, Borghi V, Di Biagio A. Magnasco L, et al. Among authors: de vito a. AIDS Res Hum Retroviruses. 2022 Jun;38(6):463-471. doi: 10.1089/AID.2021.0016. Epub 2022 Feb 10. AIDS Res Hum Retroviruses. 2022. PMID: 34969260
Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study.
Bavaro DF, De Vito A, Pasculli G, Bouba Y, Magnasco L, Pincino R, Saladini F, Lattanzio R, Corsini R, Arima S, Zazzi M, Incardona F, Rossetti B, Bezenchek A, Vanni B, Di Biagio A. Bavaro DF, et al. Among authors: de vito a. J Med Virol. 2022 Aug;94(8):3890-3899. doi: 10.1002/jmv.27754. Epub 2022 Apr 9. J Med Virol. 2022. PMID: 35355293 Free PMC article.
Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study.
De Vito A, Ricci E, Menzaghi B, Orofino G, Martinelli CV, Squillace N, Taramasso L, De Socio GV, Molteni C, Valsecchi L, Costa C, Celesia BM, Parruti G, Pellicanò GF, Sarchi E, Cascio A, Cenderello G, Falasca K, Di Biagio A, Bonfanti P, Madeddu G. De Vito A, et al. Among authors: de socio gv. Viruses. 2023 Mar 10;15(3):720. doi: 10.3390/v15030720. Viruses. 2023. PMID: 36992429 Free PMC article.
Long-acting combination of cabotegravir plus rilpivirine: A picture of potential eligible and ineligible HIV-positive individuals from the Italian ARCA cohort.
Cervo A, Russo A, Di Carlo D, De Vito A, Fabeni L, D'Anna S, Duca L, Colpani A, Fois M, Zauli B, Mancarella G, Carraro A, Bezenchek A, Cozzi-Lepri A, Santoro MM; ARCA Study Group. Cervo A, et al. Among authors: de vito a. J Glob Antimicrob Resist. 2023 Sep;34:141-144. doi: 10.1016/j.jgar.2023.07.006. Epub 2023 Jul 13. J Glob Antimicrob Resist. 2023. PMID: 37453495 Free article.
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Rossotti R, Gagliardini R, Saracino A, Lo Caputo S, Sala M, Quiros-Roldan E, Mussini C, Girardi E, Cozzi-Lepri A, Antinori A, Puoti M; NoCo Study of the Icona cohort. d'Arminio Monforte A, et al. Liver Int. 2023 Oct;43(10):2130-2141. doi: 10.1111/liv.15700. Epub 2023 Aug 31. Liver Int. 2023. PMID: 37649460 Free article.
344 results